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A B S T R A C T
Current anti-cancer drugs can cause many undesirable side effects to patients. Thus, there is a constant need to
develop alternative therapeutic drugs. Bioactive compounds derived from natural products including animals,
plants and microorganisms are being actively studied as sources for anticancer treatments. Freshwater planar-
ians are important models for stem cell research and regeneration. However, to date, no studies on the biological
activities of planaria extracts on cancer have been published. The aim of this study was to examine the potential
antitumoral activity of the extract from planaria species-Malta (PSM) on human acute myeloid leukemia (AML)
HL-60 cells. Antiproliferative activity was studied in terms of proliferation, apoptosis and differentiation. The
expression of genes involved in the regulation of these important cellular processes was also analyzed using real-
time PCR. PSM extract exhibited a selective cytotoxic effect on HL-60 cells when compared to normal lym-
phocytes. Furthermore, cell cycle analysis and Annexin V/PI assay showed that the extract induced apoptosis in
HL-60 cells. The PSM extract induced myeloid differentiation with HL-60 cells showing a decreased nucleo/
cytoplasmic ratio, an increase in nitroblue tetrazolium-positive cells, and CD11b- and CD14-positive cells.
Finally, we also found that the PSM extract increased the expression of CEBPA, CEBPB, CEBPE, SPI1, BAX,
CDKN1A and CDKN2C; whereas it reduced the expression of c-MYC and BCL2.
This is the first study to reveal the antiproliferative, cytotoxic, and differentiation potential of PSM on HL-60
cells and suggests that it may have considerable potential for development as a novel natural product-based
anticancer agent against AML.
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of diseases
characterised by impaired differentiation and clonal expansion of
myeloid progenitors in both the peripheral blood and bone marrow
(BM) [1]. In the USA, the age-adjusted incidence of AML is 4.3 per
100,000 with a mean age of 68 years [2]. The overall 5-year survival
rate for all AML sub-types with the best available treatment is about
60–75 % for children, 50–60 %, in young patients (15–39 years of age),
while in older patients it is approximately 10 % [3]. Even in patients
who achieve remission with chemotherapy, relapse occurs in two thirds
of them due to chemo-resistance and the persistence of leukemic cells
below morphologic detection [4,5]. Moreover, the unsuccessful
treatment and persistence of residual cancer stem cells in leukemia may
be attributed to the BM microenvironment niches in which these cells
are sequestered and protectedfrom the hosts immune response.
Treating acute promyelocytic leukemia (APL) with the differ-
entiating agents, all-trans retinoic acid (ATRA) and arsenic trioxide, has
greatly improved prognosis [6]. Therefore, the strategy of inducing
malignant cells to overcome their differentiation block and enter the
apoptotic pathways has become an attractive alternative to classical
cytotoxic chemotherapeutic drugs [7]. In that respect, significant em-
phasis has been placed on identifying new agents, mainly from natural
sources, that are relatively non-toxic to normal cells and effective
against cancer cells.
Natural products have been identified as a source of drugs for
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treatment of different diseases including cancer. Natural products de-
rived from plants, marine animals, or microorganisms possess anti-in-
flammatory, anti-viral and anti-cancer activities. It was reported that
74.8 % of currently used anti-cancer drugs such as taxanes, vinca al-
kaloids, and the camptothecin class of compounds are derived from
natural products [8]. Hence, screening of natural products for novel
cancer therapeutic drugs is of utmost importance.
Planarians are important models for stem cell research and re-
generation [9]. However, according to our knowledge, there are no
studies on the biological activities of these organisms on cancer cells.
Regenerative tissues are generally resistant to carcinogenic compounds
[10] and the fact that planarians are easily available in nature makes
them potentially useful in the development of potential oncology drugs,
including agents which induce differentiation and apoptosis. This pre-
sent work examines the potential antitumoral activity of a Planaria
crude extract from a Maltese species on the HL-60 AML human cell line.
2. Materials and methods
2.1. Reagents and antibodies
Dimethyl sulphoxide (DMSO), phorbol 12-myristate 13-acetate
(PMA), bisBenzimide H 33342 trihydrochloride (Hoechst 33342),
Nitroblue tetrazolium (NBT) and other principal chemicals were pur-
chased from Sigma-Aldrich (Milan, Italy). Roswell Park Memorial
Institute (RPMI) 1640 Medium and fetal bovine serum (FBS) were
purchased from BIOWEST (Meda, MB, Italy). FITC Annexin V Apoptosis
detection kit, antibodies to CD11b, CD14 and corresponding isotype
control antibodies were purchased from BD Pharmingen (Buccinasco,
Milan, Italy).
2.2. Sample collection and extract preparation
Live planarians, were collected from a woodland area in Malta
(Buskett forest). The extract preparation was adapted from McGann
et al. [11]. On day 0, starved planarians (n = 40) were placed in a
plastic container containing artificial pond water. Planarians were
transferred to a sterile 50 mL tube and all manipulations were per-
formed on ice and away from direct sunlight. The planarians were
suspended in 10 mL of ice-cold RPMI-1640 medium with inactivated
FBS and a mixture of three protease inhibitors (2 μg/mL leupeptin/2
μg/mL Aprotinin/1 mM PMSF). Organisms were homogenized for 1
min and sonicated for 30 s. The homogenate was transferred to sterile 2
mL centrifuge tubes and cell debris was removed by centrifugation and
filter-sterilisation. The protein content was assayed using the DC pro-
tein assay kit II (Bio-Rad, Laboratories, Milan, Italy) according to
manufacturer’s protocol. All extracts were stored in 1 mL aliquots in a
−80 °C freezer. This extract will be herein referred to as Planaria
species – Malta (PSM) extract.
2.3. Cell culture
Human acute myeloid HL-60 cell line (ATCC-CCL-240) was supplied
by the America Type Culture Collection (ATCC, Manassas, VA, USA).
White cells (buffy coats) of consented healthy donors were collected
from the Malta National Blood Transfusion Center. Human peripheral
blood lymphocytes were isolated from the buffy coats using density
gradient centrifugation on Histopaque-1077 (Sigma-Aldrich) at 500 g
and 20 °C for 25 min. Lymphocytes were stimulated to proliferate by
addition of 1% phytohaemagglutinin (PHA) (10 mM; Sigma-Aldrich,
Milan, Italy).
Both cell types were cultured in RPMI 1640 medium supplemented
with 10 % heat-inactivated FBS, 100 U/mL penicillin and 100 μg/mL
streptomycin (Sigma-Aldrich) at 37 °C in a humidified atmosphere and
5% CO2.
2.4. Cell proliferation and viability
HL-60 cells (1 × 105/well) were seeded in 48-well plates and
treated with different concentrations (1, 15.6, 31.25, 62.5, 125, 250,
500 and 1000 μg/mL) of PSM extract for 24−72 h. Total cell number
and viability were evaluated by Trypan blue exclusion assay.
Additionally, IC50 values were calculated for both HL-60 cells and
lymphocytes following PSM extract treatment, using the online tool
Quest Graph™ IC50 Calculator (AAT Bioquest, Inc., Sunnyvale, CA,
USA) [12] to elicit the selectivity index (SI), which describes the se-
lectivity of a compound toward the cancer cells [13]. It was calculated
based on the ratio of IC50 of proliferating lymphocytes and HL-60 cells.
2.5. Morphological examination for apoptosis and differentiation
HL-60 cells (2 × 104/well) were seeded in 96-well plates and
treated with PSM extract (62.5 μg/mL), DMSO (1.6 and 10 %) or PMA
(10 nM) (Sigma-Aldrich) for 48 h.
Cells were stained with Hoechst 33342 (5 μg/mL medium) (Sigma-
Aldrich) for 15 min at 37 °C and visualized using an appropriate filter.
Cells were evaluated on the basis of their nuclear morphology, noting
the presence of homogeneous chromatin, condensed chromatin, and
fragmented nuclei. In addition, cytospin preparations stained with
Leishman's stain were used to confirm apoptosis and/or differentiation.
2.6. Flow cytometry analysis for cell cycle distribution and apoptosis
HL-60 cells (1 × 105/well) were seeded in 48-well plates and
treated with PSM extract (62.5 μg/mL), DMSO (1.6 and 10 %) or PMA
(10 nM) for 48 h. For DNA staining, cells were collected, centrifuged,
washed with 1 × PBS and fixed with 70 % ethanol overnight at 4 °C.
They were then washed twice with 1 × PBS, digested with 100 μL
RNAase A (100 μg/mL; for 1 h at 37 °C, and stained with 200 μL PI (100
μg/mL; (Sigma-Aldrich) in the dark for 15 min at 4 °C.
Apoptosis was evaluated using FITC Annexin V Apoptosis Detection
Kit (BD Pharmingen, Buccinasco, Milan, Italy) according to manu-
facturer’s instructions. Briefly, cells were collected, centrifuged, washed
twice with 1 × PBS and resuspended in 1X Annexin V binding buffer at
a concentration of 1 × 106 cells/mL. Then, 100 μL of cell suspension
was incubated with 5 μL of Annexin V-FITC and 5 μL of PI for 15 min at
a room temperature in the dark. Viable cells were negative for both
annexin-V and PI (annexin V−/PI−; lower left quadrant), early apop-
totic cells were positive for annexin-V staining (annexin V+/PI−; lower
right quadrant), late apoptotic/necrotic cells were positive for both
annexin-V and PI staining (annexin V+/PI+; upper right quadrant) and
necrotic cells were positive for PI staining (annexin V−/PI+; upper left
quadrant).
All flow cytometry analyses were performed by FACSCalibur flow
cytometer (Becton Dickinson, Oxford, UK), and the data were analyzed
utilizing Cell Quest software. At least 1 × 104 events were acquired for
each sample.
2.7. Nitroblue tetrazolium (NBT) reduction test
HL-60 cells (2 × 104/well) were seeded in 96-well plates and
treated with PSM crude extract (62.5 μg/mL) or DMSO (1.6 %, as a
positive control) for 48 h. Next, cells were incubated with 1 mg/mL
NBT solution at 37 °C for 30 min. Then, the percentage of cells con-
taining intracellular blue-black formazan deposits were determined. In
each count, at least 200 cells were inspected using the EVOS FL Auto 2
Cell Imaging System.
2.8. Flow cytometric analysis of CD14 and CD11b
HL-60 cells (1 × 105 cells/well) were seeded in 48-well plates and
treated with PSM crude extract (62.5 μg/mL), DMSO (1.6 %) or PMA
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(10 nM) for 48 h. Cells were collected, centrifuged, washed twice with
pre-cold 1 × PBS and incubated with direct Alexa Fluor 488-labeled
anti-CD11b antibody or PE- labelled anti-CD14 antibody (or isotype
control antibodies) on ice on a rotating platform in the dark. After 30
min., cells were washed twice and detected by flow cytometry and the
data analyzed as above. Expression of cell marker was determined by
comparison with isotype control.
2.9. RNA extraction and real-time RT-PCR
Total RNA was isolated using RNeasy Kit (Qiagen, Valencia,
California, USA) according to the manufacturer's instructions. The
concentration of RNA in each sample was determined using the
Nanodrop 2000 instrument (Thermo Fisher Scientific, Waltham, USA).
Complementary DNA (cDNA) was produced from 300 ng of RNA
from each sample using the QuantiTect Reverse Transcription Kit
(Qiagen) according to the manufacturer's instructions. Real-time RT-
PCR was performed using TaqMan™Gene Expression Assays (Applied
Biosystems.Foster City, California, USA) (Table 1). Two microliters of
the diluted c-DNA were amplified in a final volume of 25 μL with 1X
TaqMan™ Gene Expression Master Mix. Thermal cycling proceeded for
2 min at 95 °C and 40 cycles at 95 °C for 15 s, followed by 60 °C for 1
min. All real-time PCR reactions were performed in triplicate. To ensure
no contamination with genomic DNA, a no reverse transcriptase control
(no RT) was included during each run of real-time RT-PCR. A negative
control (no cDNA) was also performed. Real-time PCR and data col-
lection were performed on a BioRad CFX-96 thermocycler (Bio-Rad).
The relative expressions of mRNAs were calculated using the com-
parative 2−ΔΔCt method [14] and normalized against the geometric
average expression HPRT1 and YWHAZ housekeeping genes [15].
2.10. Statistical analysis
All experiments were performed in triplicate and repeated at least
twice. The SPSS statistics software (version 20) was used for statistical
analysis. Data are presented as the median and the inter-quartile range
(IQR). Normal distribution was assessed by Kolmogorov-Smirnov test.
Since data were not normally distribution they were analyzed using the
non-parametric Kruskal-Wallis test, followed by Dunn-Bonferroni’s post
hoc analysis. Significance was accepted at a p<0.05.
3. Results
3.1. Planaria extract reduces the growth rate and viability of HL-60 cells
First, we evaluated the potential cytotoxic effects of PSM crude
extract on HL-60 cells and lymphocytes by trypan blue assay. HL-60
cells were treated for various times (24−72 h) with various doses of
PSM extract (1–1000 μg/mL).
As shown in Fig. 1A and B, PSM extract significantly reduced the
growth rate of HL-60 cells, even at 24 h, but only at 48 h was a quasi-
dose-dependent effect observed with growth inhibition of 18, 51, 64,
71, 73 and 84 % for 31.2, 62.5, 125, 250, 500 and 1000 μg/mL, re-
spectively compared to untreated cells. We also found that growth in-
hibition caused by PSM extract treatment is, only partly, due to a de-
creased viability (Fig. 1C). Interestingly, PSM extract exhibited
selective cytotoxic effects on the HL-60 cells at 48 h, compared to ac-
tivated lymphocytes (Fig. 1D). In fact, the IC50 value of the extract in
HL-60 cells was 61.037 μg/mL, while the IC50 value of the extract ac-
tivated Lymphocytes was 162.53 μg/mL (Table 2).
Based on the obtained data, all subsequent experiments were per-
formed by incubating HL-60 cells with the concentration of 62.5 μg/mL
for 48 h.
3.2. Planaria extract induces differentiation and apoptotic morphological
changes of HL-60 cells
To elucidate the mechanism by which PSM extract reduced cell
proliferation and viability in HL-60 cells, morphological analyses were
performed. In these experiments, HL-60 cells incubated with DMSO (10
%), DMSO (1.6 %) and PMA (10 nM) were used as positive controls for
apoptosis and differentiation (granulocytic and monocytic), respec-
tively. As evidenced by phase‐contrast microscopy (Fig. 2A), with re-
spect to untreated cells, incubation with PSM extract (62.5 μg/mL)
induced a decrease in the cell number and morphological changes in-
dicative of apoptosis and differentiation. As shown in Fig. 2B, fluor-
escent microscopy by Hoechst 33342 staining shows that after in-
cubation with the extract, some cells exhibited typical signs of apoptosis
such as chromatin condensation and fragmentation. To examine the
effect of PSM extract on the differentiation of HL-60 cells, we also
analyzed the morphological changes by Leishman staining. As shown in
Fig. 2C, untreated cells showed typical myeloid leukemia blast mor-
phology with large nuclei, small cytoplasm, regular cell membrane and
large nuclear/cytoplasmic ratio, while PSM extract reduced the nu-
clear/cytoplasmic ratio in HL-60 cells.
3.3. Planaria extract induces apoptosis and increases the level of sub-G0/
G1 of HL-60 cells
To further explore the effect of PSM extract on growth and cell
death of HL-60 cells flow cytometry analysis of PI-stained nuclei and
Annexin V/PI staining were performed, respectively. In these experi-
ments, HL-60 cells incubated with DMSO (10 %), DMSO (1.6 %) and
PMA (10 nM) were used as positive controls for apoptosis and differ-
entiation (granulocytic and monocytic), respectively. As shown in
Fig. 3A and B, DNA contents from flow cytometry analysis indicated
that among the untreated HL-60 cells, 46.2 % were distributed in G0/
G1 phase, 38.1 % were accumulated in S phase, 13.1 % were in G2/M
phase and only 2.6 % were sub‐G0/G1. When HL-60 cells were in-
cubated with PSM extract (62.5 μg/mL) for 48 h, the sub-G0/G1 peak
increased (16.1 %) and the S phase population decreased.
As shown in Fig. 4A and B, flow cytometry analysis showed that
PSM extract promoted apoptosis. In fact, after being treated with PSM
extract for 48 h, 22.38 % apoptotic cells (early plus late apoptotic cells)
were found in HL-60 cells, which were significantly higher than that of
untreated cells (6.24 %, p<0.05).
3.4. Induction of differentiation in HL-60 cells after treatment with Planaria
extract
In order to support the contention that PSM extract induces myeloid
differentiation in HL-60 cells, the NBT assay, a reliable marker for
differentiation of myeloid leukemia cells [16], and flow cytometry
analysis for myelomonocytic markers CD11b and CD14 [17] were
performed. In these experiments, HL-60 cells incubated with DMSO (1.6
%) and PMA (10 nM) were used as positive controls for granulocytic
and monocytic differentiation, respectively.
Table 1
Taqman® Gene Expression Assays.
GENE ASSAY ID CATALOG NUMBER
BCL2 Hs00608023_m1 4331182
BAX Hs00180269_m1 4331182
CDKN1A Hs00355782_m1 4331182
CDKN2C Hs00176227_m1 4331182
c-MYC Hs00153408_m1 4331182
SPI1 Hs02786771_m1 4331182
CEBPA Hs00269972_s1 4331182
CEBPB Hs00270923_s1 4331182
CEBPE Hs00357657_m1 4331182
HPRT1 Hs02800695 4331182
YWHAZ Hs01122445_g1 4331182
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As shown in Fig. 5A, NBT positive cells, containing blue NBT for-
mazan deposits, were increased after treatment by PSM extract (62.5
μg/mL) for 48 h. Moreover, PSM extract determined an increase in the
presence of both CD14- and CD11b-positive cells (Fig. 4B and C).
3.5. Effects of Planaria extract treatment on gene expression in HL-60 cells
We also investigated the molecular mechanisms by which the PSM
extract could inhibit proliferation and induce apoptosis and differ-
entiation in the HL-60 cell line. For this purpose, we performed re-
al‐time RT-PCR analysis to evaluate the level of expression of genes
involved in the regulation of differentiation (CEBPA, CEBPB, CEBPE,
SPI1 and c-MYC), apoptosis (BCL2 and BAX) and cell cycle (CDKN1A
and CDKN2C), which are frequently deregulated in leukemia [18–21].
In these experiments, HL-60 cells incubated with DMSO (1.6 %) and
PMA (10 nM) were used as positive controls for apoptosis and differ-
entiation, respectively.
As shown in Fig. 6A–C, the treatment with PSM extract (62.5 μg/
mL), compared with the untreated counterpart, markedly increased the
expression of CEBPA, CEBPB, CEBPE, SPI1, BAX, CDKN1A and CDKN2C;
whereas strongly reduced the expression of c-MYC and BCL2 after 24 h.
The figures also show that, after 48 h, the treatment with PSM extract
further increased the expression of CEBPE and BAX, and decreased
BCL2 and CDKN1A expression; whereas the levels of the other genes,
except for CDKN2C, did not show significant changes compared with
untreated counterpart.
4. Discussion
Increasing evidence from cancer studies indicate that bioactive
compounds derived from natural sources including animals, plants and
microorganisms may act as potentially promising therapeutic agents in
the treatment of human cancers [22–25]. In this study, the PSM crude
extract exhibited apoptotic and differentiation-inducing activity in
human HL-60 cells, a model system for studying human myeloid cell
differentiation.
Fig. 1. Effects of PSM extract on cell number (A), relative cell growth (percentage cell number of PSM treated cells relative to untreated cells) (B) and cell viability (C)
of HL-60 cells. Cells were treated with PSM extract as indicated for 72 h. (D) Effects of PSM extract on Lymphocytes and HL-60 cells after 48 h treatment.
The number of viable cells was determined by trypan blue exclusion. Data are presented as median and inter-quartile range (error bars) (n = 2 independent
experiments carried out in triplicate) and were analyzed using nonparametric Kruskal-Wallis, followed by Dunn-Bonferroni’s post hoc analysis (* p<0.05; **
p<0.001).
Table 2
Antiproliferative effects and selectivity of PSM toward HL-60 cells at 48 h.
Compound HL-60 IC
50 (μg/mL)
Activated lymphocytes IC50
(μg/mL)
SI
Planaria Species-Malta
extract
61.037 162.593 2.7a
a Selectivity Index (SI), calculated based on the ratio of IC50 activated lym-
phocytes and the HL-60 cells.
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Fig. 2. Morphological changes of HL-60 cells treated with 62.5 μg/mL of PSM extract after 48 h. (A) Phase contrast microscopy images, (B) fluorescence microscopy
images after staining with Hoechst 33342 and (C) Leishman staining assay. HL-60 cells incubated with DMSO (10 %), DMSO (1.6 %) and PMA (10 nM) were used as
positive controls for apoptosis, granulocytic and monocytic differentiation, respectively. The scale bar is 100 μm. The images were a representative of three in-
dependent experiments.
S. Suleiman, et al. Biomedicine & Pharmacotherapy 130 (2020) 110549
5
It is well known that effective and acceptable anticancer agents
have to meet various criteria, including its effects on normal cells being
relatively harmless [26]. So, the effect of PSM crude extract on HL-60
cells and on human normal proliferating lymphocytes was evaluated.
The PSM extract exhibited selective anti-proliferative effect of 2.7-fold
against HL-60 cells when compared to activated lymphocytes. This
suggests that the PSM extract could have interesting bioactive mole-
cules against cancer cells.
Following PSM treatment, HL-60 cells exhibited morphological
changes including decreased N/C ratio with irregular and clear cyto-
plasm as opposed to the high N/C ratio and regular basophilic cyto-
plasmic rim in untreated cells. The cells lacked nuclear indentations
typical of differentiated cells and resembled ‘partially differentiated’
HL-60 cells as described following treatment with arsenic trioxide [27].
Moreover, PSM treated cells resembled "paramyeloid’ cells described by
Zinzar et al. [28] with a granulocyte-like nucleus, but monocyte-like
cytoplasm. Paramyeloid cells were also described in patients with
chronic myelomoncytic leukemia [29]. These cells had cytoplasmic and
nuclear features intermediate between a monocyte and a granulocyte.
Even though PSM treated cells exhibited a monocyte-like cytoplasm and
increased expression of CD11b and CD14, typical of monocytic differ-
entiation, however, the cells did not show increased adherence to
plastic typical of monocytic differentiation as seen with PMA treatment
in this study. Interestingly, at the molecular level, studies implicating
PU.1 and C/EBPα in myeloid differentiation report that in the first 24 h,
PU.1 activates a mixed macrophage/neutrophil gene expression in
PUER cells, with cells co-expressing at least one macrophage- and
neutrophil- specific gene [30].
Expression studies further confirm that, when compared to un-
treated HL-60 cells, PSM treated HL-60 cells respond by increased ex-
pression of myeloid transcription factors with commitment towards the
myelomonocytic route. Identification of molecules leading to activation
Fig. 3. Effects of PSM extract (62.5 μg/mL) treatment on cell cycle distribution in HL-60 cells after 48 h. (A) Histogram plots of flow cytometry analysis performed in
HL-60 cells. (B) Graph summarizing the cell cycle distribution. HL-60 cells incubated with DMSO (10 %), DMSO (1.6 %) and PMA (10 nM) were used as positive
controls for apoptosis, granulocytic and monocytic differentiation, respectively. Data are presented as median and inter-quartile range (error bars) (n = 2 in-
dependent experiments carried out in triplicate) and were analyzed using nonparametric Kruskal-Wallis, followed by Dunn-Bonferroni’s post hoc analysis (* p<0.05;
** p<0.001).
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of transcription factors is another strategy that is actively studied for
novel therapeutic agents in the fight against cancer.
PSM treatment also caused apoptosis of HL-60 cells with apoptotic
cell nuclei evident following Hoechst 33342 staining and the appear-
ance of a cell population in sub-G0/G1 phase of the cell cycle, together
with increased and sustained expression of the pro-apoptotic BAX gene
and significant repression of the anti-apoptotic BCL2 gene. Even though
PSM did not cause cell cycle arrest at the G0/G1 phase typical of dif-
ferentiation agents such as ATRA and PMA, however, at 48 h treatment,
PSM caused partial differentiation of HL-60 cells and induced apoptosis.
Many studies reflect on cell cycle arrest in terms of ‘terminal dif-
ferentiation’, when cells no longer divide [31]. However, the exact re-
lationship between cell proliferation and differentiation remains un-
resolved with actively proliferating cells acquiring characteristics of
differentiating cells, including the acquisition of myeloid surface anti-
gens and expression of molecular characteristics [32]. Brown et al. [33]
on HL-60 cells, reported that differentiation and cell proliferation are
regulated simultaneously but independently, and cells commit to dif-
ferentiation long before cell cycle arrest, with differentiation not re-
stricted to any particular segment of the cell cycle. In other studies, HL-
60 cells traversed two to three cell cycles prior to terminal differ-
entiation and cell cycle arrest following ATRA treatment. [34,35].
The transient expression of CDKN1A, SPI1, and c-MYC could in-
dicate that PSM-induced differentiation of HL-60 cells is unstable, with
possible retro differentiation and/or accumulation of PSM resistant HL-
60 cells. This might indicate that a constant stimulation by PSM is re-
quired to maintain growth arrest and differentiation. Similar results
were described following treatment of U937 cells with PMA [36].
Fig. 4. Apoptotic activity of HL-60 cells in response to treatment with DMSO (10 %), DMSO (1.6 %), PMA (10 nM) and PSM extract (62.5 μg/mL) for 48 h. Apoptotic
cells were quantified by flow cytometry after staining with PI and FITC-Annexin V. Four fractions (PI−/Annexin V−, PI−/Annexin V+, PI+/Annexin V+, PI+/
Annexin V−) were analyzed. (A) Representative flow cytometric dot plots. (B) The summary of populations stained with only Annexin V (early apoptosis) and with
both Annexin V and PI (late apoptosis). Data are presented as median and inter-quartile range (error bars) (n = 2 independent experiments carried out in triplicate)
and were analyzed using nonparametric Kruskal-Wallis, followed by Dunn-Bonferroni’s post hoc analysis (* p<0.05; ** p<0.001).
S. Suleiman, et al. Biomedicine & Pharmacotherapy 130 (2020) 110549
7
Fig. 5. PSM extract-induced cell differentiation in HL-60 cells. (A) Nitroblue tetrazolium (NBT) reduction assay. Cells were treated with PSM extract (62.5 μg/mL) for
48 h. Microscopy images display cells containing intracellular blue-black formazan deposits (scale bar =100 μm). Graph summarizing the percentages of NBT
positive cells. HL-60 cells incubated with DMSO (1.6 %) were used as positive controls for granulocytic differentiation. (B) Cytometric analyses showing cell surface
expression of CD11b (top panels) and CD14 (bottom panels) in HL-60 cells treated with DMSO (10 %), DMSO (1.6 %), PMA (10 nM) and PSM extract (62.5 μg/mL)
for 48 h. (C) Graph summarizing both CD11b and CD14 reactivity.
Data are presented as median and inter-quartile range (error bars) (n = 2 independent experiments carried out in triplicate) and were analyzed using nonparametric
Kruskal-Wallis, followed by Dunn-Bonferroni’s post hoc analysis (* p<0.05; ** p<0.001).
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Furthermore, recovery of c-MYC expression has been reported in other
studies whereby expression of c-MYC was drastically reduced within a
few hours during differentiation with nicotinamide and DMSO-treated
HL-60 cells with subsequent increase in expression, after which the
expression levels remained low [37,38]. It was suggested that two
distinct mechanisms of transcriptional control operate on c-MYC during
differentiation of HL-60 cells with an early reversible downregulation
and a late non-reversible downregulation following treatment with
differentiating agents [38].
The reduced proportion of PSM treated cells in the S phase and
increase in sub-G0/G1 can be indicative of cells that are no longer
traversing the S- to G2/M phase transition and hence have undergone
cell cycle arrest prior to induction of apoptosis. This could be attributed
to a mechanism similar to chemotherapeutic drugs whereby following
treatment, DNA breakages accumulate primarily at the S- phase of the
cell cycle, unable to proceed to the G2/M phase, with resultant apop-
totic cell death [39].
Overall, our findings show that PSM crude extract possesses anti-
tumor activity through anti-proliferative, apoptotic and differentiation-
inducing actions on HL-60 cells in vitro (Fig. 7).
5. Conclusion
In conclusion, we provide evidence showing that a crude extract
Fig. 6. Differentially expression genes in response to PSM extract treatment in HL-60 cells. Cells were treated with PSM extract (62.5 μg/mL) for indicated times.
mRNA expression of genes involved in cell differentiation (A), apoptosis (B) and cell cycle (C) regulation was determined by Real-time RT-PCR. HL-60 cells incubated
with DMSO (1.6 %) and PMA (10 nM) were also used as positive controls. Relative transcript levels were determined using the 2−ΔΔCt method and normalized to
HPRT1 and YWHAZ reference genes. Expression levels in untreated cells were treated as calibrators. Data are presented as median and inter-quartile range (error
bars) (n = 2 independent experiments carried out in triplicate) and were analyzed using nonparametric Kruskal-Wallis, followed by Dunn-Bonferroni’s post hoc
analysis (* p<0.05; ** p<0.001).
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from a local planarian species could be used to develop new anti-cancer
molecules for the treatment of AML. Furthermore, studies have reported
on the anti-cancer effects of several regenerative earthworm species,
and it is possible that planarians possess similar bioactive molecules
including enzymes, proteins, unsaturated fatty acids, peptides, vita-
mins, among others [40–43]. In the future, the morphological and
molecular characterization of the planaria species in Malta will be
carried out. This will help not only in species identification but whether
different species exhibit different effects on cancer cells. Also, identi-
fication of the bioactive molecules will be carried and tested for pos-
sible synergistic, antagonistic, and or additive effects on human leu-
kemia cells in vitro and in vivo.
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